Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$11,642.00
May 21, 2024
For-profit organization
IP Assist: Intellectual Property Strategy Engagement
1018795
The Project will support development of intellectual property capacity within the Firm.
$5,176,172.00
Sep 1, 2022
For-profit organization
COVID-19 Rapid Response: Assessment of the Effect of lung-directed Site-Specific Immunomodulator (SSI) in clinical trial QBKPN-CV-01: Assessment of the Effect of QBKPN Site-Specific Immunomodulator (SSI) on Innate Immunity and COVID-19 Vaccine Immune Response and Maintenance in Adults 65 Years of Age or Older
995430
This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mortality from COVID-19 in a test population of adults 65 years of age or older in long term care or assisted living facilities.
$37,933.00
Dec 20, 2020
For-profit organization
Innovation Assistance Program – Round 2.5
966282
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
$2,780,109.00
Dec 1, 2020
For-profit organization
COVID-19 Rapid Response: Preclinical studies for safety and efficacy of lung-directed Site-Specific Immunomodulator (SSI) in COVID-19 relevant animal model
961167
This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.
$38,170.00
Aug 17, 2020
For-profit organization
COVID-19 Rapid Response: Novel Immune Therapeutic for the Prevention and Treatment of COVID-19
955668
Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specific Immunomodulator (SSI), for use in a planned clinical trial for COVID-19 prevention.
$85,232.00
Jun 25, 2020
For-profit organization
Innovation Assistance Program - Round 2
960196
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
$71,148.00
Apr 1, 2020
For-profit organization
Innovation Assistance Program
951033
The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.
$153,855.00
Mar 1, 2019
For-profit organization
Enhancing eradication of solid tumours using Site-Specific Immunomodulators and engineered cancer-specific T cells
924855
This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomodulators (SSIs), are used in conjunction as neoadjuvant therapy.
$4,500.00
May 1, 2018
Individual or sole proprietorship
Experience Awards
11020182019Q2182
NSERC’s Experience Awards (previously Industrial Undergraduate Student Research Awards [IUSRA]) offer organizations access to talented natural sciences and engineering undergraduate students for a work term. This cost-shared program allows students to address organization-specific R&D challenges while gaining valuable industrial experience. Experience Awards also let organizations identify potential future full-time employees.
$4,500.00
Feb 7, 2018
SSI efficacy in cancer and inflammatory bowel disease animal models
USRAI